Crizotinib (Xalkori®), which specifically targets and inhibits kinase activity of EML4-ALK, has been developed as a targeted therapy for NSCLC patients with EML4-ALK fusion oncogenes, which account for 3 to 7% of NSCLC mutations4,5. Here, ALK is linked to non-small cell lung carcinoma.